KR20180037261A - Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체 - Google Patents

Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체 Download PDF

Info

Publication number
KR20180037261A
KR20180037261A KR1020187006526A KR20187006526A KR20180037261A KR 20180037261 A KR20180037261 A KR 20180037261A KR 1020187006526 A KR1020187006526 A KR 1020187006526A KR 20187006526 A KR20187006526 A KR 20187006526A KR 20180037261 A KR20180037261 A KR 20180037261A
Authority
KR
South Korea
Prior art keywords
diacetyl
disease
syndrome
fibrosis
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187006526A
Other languages
English (en)
Korean (ko)
Inventor
칼 오스카 브라운 Iii
치-쾅 첸
징-위 리
웨이-슈 루
Original Assignee
티더블유아이 바이오테크놀로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티더블유아이 바이오테크놀로지 인코포레이티드 filed Critical 티더블유아이 바이오테크놀로지 인코포레이티드
Publication of KR20180037261A publication Critical patent/KR20180037261A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020187006526A 2015-08-17 2016-08-17 Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체 Ceased KR20180037261A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206102P 2015-08-17 2015-08-17
US62/206,102 2015-08-17
PCT/US2016/047272 WO2017031161A1 (en) 2015-08-17 2016-08-17 Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex

Publications (1)

Publication Number Publication Date
KR20180037261A true KR20180037261A (ko) 2018-04-11

Family

ID=58051269

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006526A Ceased KR20180037261A (ko) 2015-08-17 2016-08-17 Asc의 발현, nlrp3의 발현, 및/또는 nlrp3 인플라마솜 복합체의 형성 저해용 디아세레인 또는 이의 유사체

Country Status (13)

Country Link
US (1) US10195170B2 (https=)
EP (2) EP3337782A4 (https=)
JP (3) JP6887987B2 (https=)
KR (1) KR20180037261A (https=)
CN (1) CN108349867B (https=)
AU (2) AU2016308121A1 (https=)
BR (1) BR112018003212A2 (https=)
CA (1) CA2994987C (https=)
IL (1) IL257379A (https=)
MX (1) MX2018002049A (https=)
RU (1) RU2729066C2 (https=)
TW (1) TWI743047B (https=)
WO (1) WO2017031161A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
EP3562506A4 (en) 2016-12-29 2021-01-06 University of Miami METHOD TO MODULATE INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
CN110177547B (zh) 2017-01-18 2022-09-27 台睿生物科技股份有限公司 用于治疗炎症性肠病和肠结肠炎的组合物
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
JP2020530472A (ja) * 2017-08-11 2020-10-22 オラテック セラピューティクス リミティド ライアビリティ カンパニー シュニッツラー症候群の治療方法
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2020010273A1 (en) 2018-07-03 2020-01-09 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
IL283127B1 (en) 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
ES2975968T3 (es) * 2018-12-03 2024-07-18 Smilebiotek Zhuhai Ltd Galato de octilo y ésteres del mismo para uso en el tratamiento y prevención de la degeneración macular asociada a la edad causada por Bacillus Megaterium
EA202191968A1 (ru) 2019-01-14 2021-11-16 Кадила Хелзкэр Лимитед Новые замещенные производные сульфонилмочевины
CN109833292A (zh) * 2019-02-23 2019-06-04 河南省人民医院 一种双醋瑞因滴眼液及其用途
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN110179865A (zh) * 2019-06-26 2019-08-30 广州中医药大学(广州中医药研究院) 一种大黄蒽醌类成分的制备方法及其应用
CN110787157A (zh) * 2019-11-27 2020-02-14 中南民族大学 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
JP7459298B2 (ja) * 2020-01-06 2024-04-01 シーサン・セラピューティクス 細胞透過性核酸複合体を有効成分として含有する黄斑変性の予防又は治療用組成物
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
CN115616216B (zh) * 2021-07-15 2025-08-12 华南理工大学 抑制或阻断faah与nlrp3之间相互作用的制剂的用途
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128317A1 (en) 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
GB0404953D0 (en) * 2004-03-04 2004-04-07 Arakis Ltd Pro-drugs
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
CN102060809B (zh) * 2009-05-01 2015-05-20 常州高新技术产业开发区三维工业技术研究所有限公司 一种大黄酸衍生物及其制备和用途
NZ602583A (en) * 2010-04-08 2014-10-31 Twi Biotechnology Inc Methods of using diacerein as an adjunctive therapy for diabetes
WO2012013670A1 (en) * 2010-07-29 2012-02-02 University Of Geneva Process for the esterification of hyaluronic acid with hydrophobic organic compounds
WO2012125359A1 (en) * 2011-03-11 2012-09-20 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
WO2013007763A1 (en) * 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
US8652540B2 (en) * 2012-06-04 2014-02-18 Hong Kong Baptist University Method of using rhein for treating fibrotic conditions and tumors
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
KR101486147B1 (ko) * 2013-07-09 2015-01-23 주식회사 엘지생활건강 Tslp 분비 저해능 및 이에 의한 알러지성 질환의 개선능을 가지는 조성물
HK1249057A1 (zh) * 2015-07-01 2018-10-26 安成生物科技股份有限公司 双醋瑞因或大黄酸局部用制剂及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102075724B1 (ko) * 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도

Also Published As

Publication number Publication date
EP4147694A1 (en) 2023-03-15
JP2018523687A (ja) 2018-08-23
JP2021121605A (ja) 2021-08-26
CN108349867A (zh) 2018-07-31
RU2729066C2 (ru) 2020-08-04
CN108349867B (zh) 2021-03-09
JP2023078360A (ja) 2023-06-06
AU2016308121A1 (en) 2018-03-01
RU2018109237A (ru) 2019-09-19
EP3337782A1 (en) 2018-06-27
CA2994987A1 (en) 2017-02-23
US10195170B2 (en) 2019-02-05
EP3337782A4 (en) 2019-04-03
IL257379A (en) 2018-04-30
RU2018109237A3 (https=) 2019-12-31
TWI743047B (zh) 2021-10-21
AU2021200117A1 (en) 2021-03-18
TW201717927A (zh) 2017-06-01
MX2018002049A (es) 2018-06-15
AU2021200117B2 (en) 2023-09-28
HK1254388A1 (zh) 2019-07-19
WO2017031161A1 (en) 2017-02-23
BR112018003212A2 (en) 2018-09-25
CA2994987C (en) 2023-09-26
JP6887987B2 (ja) 2021-06-16
US20170049733A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
AU2021200117B2 (en) Diacerein or its analogs for inhibiting expression of ASC, NLRP3, and/or formation of NLRP3 inflammasome complex
JP2017512757A (ja) 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法
KR20150125647A (ko) 고용체 조성물들 및 만성염증에서의 이의 용도
KR20210002573A (ko) 간 질환에 호중구 엘라스타제 저해제의 사용
KR20170140383A (ko) 펩티드 조성물 및 사용 방법
RS57970B1 (sr) Tretman intrahepatičkih holestatskih oboljenja
KR101722432B1 (ko) 류마티스성 관절염 등 자가면역 질환 치료의 개선방법
EP3028704A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
US20210252025A1 (en) Synergic pharmaceutical combination of a selective inhibitor of cyclooxygenase-2 and an anthraquinone derivative
EP4480484A1 (en) Indole compound for treating interstitial cystitis
US11628163B2 (en) 1-piperidinepropionic acid for treating a fibrosing disease
HK1259125A1 (zh) 治疗和/或预防与血液相关病症的方法和制剂
JP2021533128A (ja) 神経変性障害を治療するための方法
HK1254388B (zh) 用於抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
RU2791025C2 (ru) Способ лечения боли или интерстициального цистита с использованием индольного соединения
JP2025502488A (ja) イソキサゾリン誘導体を含む注射用製剤
RU2779839C2 (ru) Композиции твердых растворов и их применение при хроническом воспалении

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210810

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231219

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D